Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05560386
Other study ID # GCO 17-2272
Secondary ID 5R03DK118302-02
Status Completed
Phase N/A
First received
Last updated
Start date August 1, 2020
Est. completion date March 31, 2022

Study information

Verified date December 16, 2023
Source Icahn School of Medicine at Mount Sinai
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The number of youth with type 2 diabetes in the U.S. is projected to increase by a staggering 49 percent by 2050, with higher rates among minority youth. The Diabetes Prevention Program (DPP) is recognized as a sentinel study demonstrating the effectiveness of lifestyle interventions for diabetes prevention among pre-diabetic adults but has not yet been replicated in youth. In addition, such intensive interventions are often not sustainable in high risk communities with limited resources. One strategy that has been successfully employed in adults from such communities is peer based health education. However, there have been no peer led interventions in ethnic minority teens and no interventions focused specifically on weight loss for diabetes prevention. Another challenge identified in existing youth health intervention programs is keeping youth engaged to enhance program participation and impact. One potential strategy is the use of mobile technologies (text messaging, mobile applications, social media) to support weight management programs, but to date use of such technologies has largely not been studied in youth. The Principal Investigator's NIH Mentored Patient-Oriented Research Career Development Award (K23) aimed to use CBPR to develop and pilot test a peer-led diabetes prevention intervention incorporating mobile health technologies for at-risk adolescents. Based on results of focus groups which explored strategies for using peer educators and mHealth tools as part of a group lifestyle change program, the researchers did not find existing tools with all the features and functionalities required by users. The investigators therefore began working with teen stakeholders to create a new text messaging platform to support participants as the teens complete the intervention. This R03 research proposal aims to bring together clinical, technology and community experts to further develop and evaluate the mobile health platform. This will provide important pilot data to refine and disseminate the intervention for a larger RCT to be tested in a future R01. Specific Aims: 1. Synthesize real-time data and analytics and conduct user interface (UI) testing to refine and enhance features of the prototype text messaging platform. 2. Investigate the potential for the developed platform to be used as an adjunct to a group educational intervention by examining whether level of use, user satisfaction, and degree of engagement with the platforms modifies behavioral and clinical outcomes.


Recruitment information / eligibility

Status Completed
Enrollment 54
Est. completion date March 31, 2022
Est. primary completion date March 31, 2022
Accepts healthy volunteers No
Gender All
Age group 13 Years to 19 Years
Eligibility Inclusion Criteria: For Aim 1 (user interface testing): - Ages 13-19 years; - English speaking with English or Spanish speaking parent/guardian; - Affiliated with East Harlem. For Aim 2 (virtual workshop): - Ages 13-19 years; - English speaking with English or Spanish speaking parent/guardian; - Affiliated with East Harlem; - Overweight/obese based on measured body mass index; - prediabetic based on hemoglobin A1c Exclusion Criteria: - Medical or developmental conditions which would make it difficult to participate in a virtual group educational program

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Text messaging
text messaging content to support diabetes prevention.
Virtual workshop
virtual workshop content to support diabetes prevention.

Locations

Country Name City State
United States Icahn School of Medicine at Mount Sinai New York New York

Sponsors (2)

Lead Sponsor Collaborator
Icahn School of Medicine at Mount Sinai National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Body Mass Index (BMI) Maintenance or reduction of BMI after completion of the virtual diabetes prevention program.
BMI is a person's weight in kilograms divided by the square of height in meters. A high BMI can indicate high body fatness and may lead to health problems.
baseline
Primary Body Mass Index (BMI) Maintenance or reduction of BMI after completion of the virtual diabetes prevention program.
BMI is a person's weight in kilograms divided by the square of height in meters. A high BMI can indicate high body fatness and may lead to health problems.
end of study at 3 months
Secondary Number of Participants Who Were Responsive to Interactive 2-way Messages Text Messaging Program - Number of participants who were responsive to interactive 2-way messages 12 Weeks
Secondary Number of Participants Who Were Engaged Every Week Text Messaging Program - Number of participants who initially consented to the study who were engaged every week 12 weeks
Secondary Level of Engagement Text Messaging Program - Level of engagement as measured by responsiveness to 2-way interactive messages.
Percent responding over the 12 weeks.
Over 12 weeks of time
Secondary Hemoglobin A1c A1C is a lab test that shows the average level of blood sugar (glucose) over the previous 3 months. It shows how well a person is controlling blood sugar to help prevent complications from diabetes.
Hemoglobin A1c (per American Diabetes Association): normal is 4-5.6% (5.7-6.4% is prediabetes and >6.5% is diabetes level)
baseline
Secondary Hemoglobin A1c A1C is a lab test that shows the average level of blood sugar (glucose) over the previous 3 months. It shows how well a person is controlling blood sugar to help prevent complications from diabetes.
Hemoglobin A1c (per American Diabetes Association): normal is 4-5.6% (5.7-6.4% is prediabetes and >6.5% is diabetes level)
end of study at 3 months
Secondary Body Fat % For girls normal range is 16-31% for ages 13-18 years; for boys normal range is 10-22% for ages 13-18 years. Higher % indicates higher metabolic risk. baseline
Secondary Body Fat % For girls normal range is 16-31% for ages 13-18 years; for boys normal range is 10-22% for ages 13-18 years. Higher % indicates higher metabolic risk. end of study at 3 months
Secondary Waist Circumference Waist circumference for boys/girls 10th-90th percentile ranges from 63.0-116.5 cm. Higher percentile indicates higher metabolic risk. baseline
Secondary Waist Circumference Waist circumference for boys/girls 10th-90th percentile ranges from 63.0-116.5 cm. Higher percentile indicates higher metabolic risk. end of study at 3 months
Secondary Blood Pressure - Systolic and Diastolic Blood Pressures Blood pressure is the pressure of circulating blood against the walls of blood vessels. Higher blood pressure may indicate higher metabolic risk. baseline
Secondary Blood Pressure - Systolic and Diastolic Blood Pressures Blood pressure is the pressure of circulating blood against the walls of blood vessels. Higher blood pressure may indicate higher metabolic risk. end of study at 3 months
Secondary Total Cholesterol (<200 is low risk, 200-239 borderline, >240 high risk). baseline
Secondary Total Cholesterol (<200 is low risk, 200-239 borderline, >240 high risk). end of study at 3 months
Secondary Low Density Lipoprotein (LDL) (<100 is best, 100-129 is acceptable for those with no health issues, 130-159 is borderline, 160-189 is high). baseline
Secondary Low Density Lipoprotein (LDL) (<100 is best, 100-129 is acceptable for those with no health issues, 130-159 is borderline, 160-189 is high). end of study at 3 months
Secondary High Density Lipoprotein (HDL) (>60 is good, 40-59 is normal, <40 is associated with increased risk of heart disease). baseline
Secondary High Density Lipoprotein (HDL) (>60 is good, 40-59 is normal, <40 is associated with increased risk of heart disease). end of study at 3 months
Secondary Triglycerides (<150 is normal, 150-199 is borderline, 200-499 is high). baseline
Secondary Triglycerides (<150 is normal, 150-199 is borderline, 200-499 is high). end of study at 3 months
Secondary Portion Control This is a validated scale to measure how well someone controls the amount of food they eat. The total scale value ranges from 8-32; higher score indicates better portion control. baseline
Secondary Portion Control This is a validated scale to measure how well someone controls the amount of food they eat. The total scale value ranges from 8-32; higher score indicates better portion control. end of study at 3 months
Secondary Self-Efficacy Healthy Eating Subscale 1 This is a validated scale to measure how confident someone is that they can eat healthy. The total scale value ranges from 8-40; higher score indicates higher self-efficacy. baseline
Secondary Self-Efficacy Healthy Eating Subscale 1 This is a validated scale to measure how confident someone is that they can eat healthy. The total scale value ranges from 8-40; higher score indicates higher self-efficacy. end of study at 3 months
Secondary Self-Efficacy Health Eating Subscale 2 This is a validated scale to measure how confident someone is that they can eat healthy. The total scale value ranges from 5-25; higher score indicates higher self-efficacy. baseline
Secondary Self-Efficacy Health Eating Subscale 2 This is a validated scale to measure how confident someone is that they can eat healthy. The total scale value ranges from 5-25; higher score indicates higher self-efficacy. end of study at 3 months
Secondary Perceived Barriers to Health Eating This is a scale to measure participants perceptions about the barriers they face for eating healthy. The total scale value ranges from 4-16; higher score indicates more perceived barriers. baseline
Secondary Perceived Barriers to Health Eating This is a scale to measure participants perceptions about the barriers they face for eating healthy. The total scale value ranges from 4-16; higher score indicates more perceived barriers. end of study at 3 months
Secondary Daily MVPA Hours Daily MVPA (moderate to vigorous physical activity) hours of moderate to vigorous physical activity (daily, average over the last week) baseline
Secondary Daily MVPA Hours Daily MVPA (moderate to vigorous physical activity) hours of moderate to vigorous physical activity (daily, average over the last week) end of study at 3 months
Secondary Strenuous Exercise Hours Hours of strenuous physical activity (daily, average over the last week). baseline
Secondary Strenuous Exercise Hours Hours of strenuous physical activity (daily, average over the last week). end of study at 3 months
Secondary Moderate Exercise Hours Hours of moderate physical activity (daily, average over the last week). baseline
Secondary Moderate Exercise Hours Hours of moderate physical activity (daily, average over the last week). end of study at 3 months
Secondary Mild Exercise Hours Hours of mild physical activity (daily, average over the last week). baseline
Secondary Mild Exercise Hours Hours of mild physical activity (daily, average over the last week). end of study at 3 months
Secondary Time Spent Doing Physically Active Chores Hours of physically active chores (daily, average over the last week). baseline
Secondary Time Spent Doing Physically Active Chores Hours of physically active chores (daily, average over the last week). end of study at 3 months
Secondary Time Spent Walking Hours of walking (daily, average over the last week). baseline
Secondary Time Spent Walking Hours of walking (daily, average over the last week). end of study at 3 months
Secondary Time Spent Doing Unscheduled/Unstructured Physical Activity Hours of Unscheduled/unstructured PA (daily, average over the last week). baseline
Secondary Time Spent Doing Unscheduled/Unstructured Physical Activity Hours of Unscheduled/unstructured PA (daily, average over the last week). end of study at 3 months
Secondary Screentime -Weekday Screen time on the weekdays in hours (daily, average) - Combined TV, computer, video games, smartphone/Ipad/etc. baseline
Secondary Screentime -Weekday Screen time on the weekdays in hours (daily, average) - Combined TV, computer, video games, smartphone/Ipad/etc. end of study at 3 months
Secondary Screentime-weekend Screen time on the weekend in hours (daily, average) - Combined TV, computer, video games, smartphone/Ipad/etc. baseline
Secondary Screentime-weekend Screen time on the weekend in hours (daily, average) - Combined TV, computer, video games, smartphone/Ipad/etc. end of study at 3 months
Secondary Physical Activity Self Efficacy Score This is a validated scale to measure how confident participants are that they can be physically active. The total scale value ranges from 6-24; higher score indicates higher self-efficacy. baseline
Secondary Physical Activity Self Efficacy Score This is a validated scale to measure how confident participants are that they can eat healthy. The total scale value ranges from 6-24; higher score indicates higher self-efficacy. end of study at 3 months
Secondary Perceived Barriers to Physical Activity Score This is a scale to measure participants perceptions about the barriers they face for being physically active. The total scale value ranges from 8-32; higher score indicates more perceived barriers. baseline
Secondary Perceived Barriers to Physical Activity Score This is a scale to measure participants perceptions about the barriers they face for eating healthy. The total scale value ranges from 8-32; higher score indicates more perceived barriers. end of study at 3 months
Secondary Self-Image Score Total range score from 6-24; higher score indicates better self-image baseline
Secondary Self-Image Score Total range score from 6-24; higher score indicates better self-image end of study at 3 months
Secondary Depression Score Total range score from 6-18; higher score indicates more depression symptoms baseline
Secondary Depression Score Total range score from 6-18; higher score indicates more depression symptoms end of study at 3 months
Secondary Body Satisfaction Score Total range score from 10-60; higher score indicates higher body satisfaction baseline
Secondary Body Satisfaction Score Total range score from 10-60; higher score indicates higher body satisfaction end of study at 3 months
Secondary Emotional Eating Score Total range score from 5-20; higher score indicates more emotional eating baseline
Secondary Emotional Eating Score Total range score from 5-20; higher score indicates more emotional eating end of study at 3 months
See also
  Status Clinical Trial Phase
Completed NCT05219994 - Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum N/A
Completed NCT04056208 - Pistachios Blood Sugar Control, Heart and Gut Health Phase 2
Completed NCT02284893 - Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone Phase 3
Completed NCT04274660 - Evaluation of Diabetes and WELLbeing Programme N/A
Active, not recruiting NCT05887817 - Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR) Phase 4
Active, not recruiting NCT05566847 - Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Completed NCT04965506 - A Study of IBI362 in Chinese Patients With Type 2 Diabetes Phase 2
Recruiting NCT06115265 - Ketogenic Diet and Diabetes Demonstration Project N/A
Active, not recruiting NCT03982381 - SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes Phase 4
Completed NCT04971317 - The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages N/A
Completed NCT04496154 - Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood N/A
Completed NCT04023539 - Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Enrolling by invitation NCT05530356 - Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
Completed NCT04097600 - A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets Phase 1
Completed NCT03960424 - Diabetes Management Program for Hispanic/Latino N/A
Completed NCT05378282 - Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
Active, not recruiting NCT06010004 - A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Phase 3
Completed NCT03653091 - Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes N/A